In the fight against COVID-19, PIMS Hydroxychloroquine (subsidiary of PureIMS) – together with (among others) the University of Groningen, UMCG and IMDS – is working feverishly on inhaled hydroxychloroquine. Following pulmonary administration, we expect a much greater effect of the drug with a lower chance of side effects, because it is administered directly to the […]